MAR 24, 2019 01:37 AM PDT

Drug Combination for Pediatric Low-grade Glioma

WRITTEN BY: Nouran Amin

Scientists at the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a new drug combination treatment targeted at resistant and recurrent low-grade gliomas particularly in pediatric populations.

The drug combination was shown to slow tumor growth and eradicate tumor cells in laboratory and mouse models. The treatment consists of carboplatin--a standard chemotherapeutic drug that works well against brain tumors, and everolimus—an inhibitory drug that targets an enzyme called mTOR known to fuel tumor growth."We saw dramatic growth inhibition after only a low concentration of everolimus was combined with the carboplatin," says Eric Raabe, M.D., Ph.D., associate professor of oncology and pediatric brain tumor expert at the Johns Hopkins Kimmel Cancer Center.

"We found that everolimus disrupted a key mechanism the cancer cells use to detoxify carboplatin. The ability of everolimus to increase the power of carboplatin suggests this combination could be used effectively in patients."

 

The introduction of everolimus with carboplatin treatment induces DNA damage in tumor cells and kills them. Credit: Johns Hopkins Kimmel Cancer Center

 

Findings of the drug combination study were published Neuro-Oncology and show increased DNA damage in tumor cells followed by cell death in laboratory models. The drug combination showed similar results in mouse models with no added toxicity.

In pediatric low-grade glioma, the most common form of brain tumors in children, surgical interventions for treatment are risky and can affect near optic nerves. However, the drug combination could serve as an effective treatment option.

"The current nationwide clinical study of everolimus in pediatric low-grade glioma requires that some tumor tissue from each patient be evaluated for expression of mTOR markers that might predict response to everolimus," Raabe says. "In this way, we hope to figure out who is most likely to respond to the drug, so that we can move closer to our goal of giving the right medicine to the right patient at the right time. In the future, we may be able to give everolimus along with carboplatin to patients with high-level mTOR expression. Based on our research, we predict that these tumors will likely be resistant to carboplatin unless we simultaneously block mTOR."

Source: John Hopkins Medicine

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 17, 2019
Drug Discovery & Development
NOV 17, 2019
Peptide-Based Therapeutics Advances Alzheimer Disease Research
Affecting 44 million individuals globally, Alzheimer’s disease (AD) is a form of dementia characterized by loss of brain cells, inflammation and vasc...
NOV 17, 2019
Drug Discovery & Development
NOV 17, 2019
Researchers Can Now Reverse Skin Cancer
Ten years ago, just 5% of people with advanced melanoma (skin cancer) lived more than five years after being diagnosed. Now however, researchers from the I...
NOV 17, 2019
Cannabis Sciences
NOV 17, 2019
CBD Alleviates Angelman Syndrome Seizures in Mice Trial
CBD has already been shown to be effective as an anti-anxiety, antipsychotic and anti-epileptic substance. Can it help youth and adults with a rare neurolo...
NOV 17, 2019
Technology
NOV 17, 2019
New Encapsulation Technology
Research at the University of Waterloo has concluded new encapsulation technology that can offer an inexpensive, and effective method for coating liquid me...
NOV 17, 2019
Drug Discovery & Development
NOV 17, 2019
How Fluorescent Probes Can Enhance Drug Delivery
Researchers at Cornell University are working on improving the trial-and-error process that is implicated in finding effective molecules for drug delivery....
NOV 17, 2019
Drug Discovery & Development
NOV 17, 2019
Promising Results for New Vaccine Against Dengue Fever
Dengue fever is an illness transmitted by mosquito bites. Affecting around 390 million people per year, if left untreated, its mortality rate is 20%. Altho...
Loading Comments...